Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis c Clear all

Conditions: Hepatitis C, Transplantation Disease Transmission
Interventions: Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Chronic Disease, Hepatitis C, Stress Disorders, Post-Traumatic
Interventions: Individual psychotherapy, Telehealth Intervention; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Hepatitis C, Hepatocellular Carcinoma
Interventions: Not listed
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 37 more

Conditions: Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
Interventions: sofosbuvir/velpatasvir; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: HEPATITIS C (HCV)
Interventions: PF-868554; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida

Conditions: Hepatitis C, Chronic
Interventions: BI 207127, BI 201335, Ribavirin, BI 207217; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 12
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 9 more

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 34
States / cities: La Jolla, California • Long Beach, California • Sacramento, California + 28 more

Conditions: Hepatitis C Virus
Interventions: BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more

Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7
Interventions: Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab, Ribavirin; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liver Transplant; Complications, Hepatitis C
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Hepatitis C, Chronic Hepatitis B
Interventions: Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Little Rock, Arkansas • Chapel Hill, North Carolina

Conditions: Hepatitis C, Chronic
Interventions: peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 91
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more

Conditions: Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
Interventions: erythropoietin, GCSF; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: Telaprevir, Peginterferon alfa-2a, Ribavirin, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Timothy Morgan, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: Long Beach, California • Minneapolis, Minnesota • Kansas City, Missouri + 1 more

Conditions: Hepatitis, Hepatitis C
Interventions: Filibuvir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 30
States / cities: Anaheim, California • Coronado, California • La Jolla, California + 22 more

Conditions: Hepatitis C Infection, HIV Infection
Interventions: Nitazoxanide With Pegylated Interferon And Ribavirin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Anaheim, California • Coronado, California • San Jose, California + 7 more

Conditions: HCV Infection
Interventions: EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules, Elbasvir Oral Granules; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more

Conditions: HIV Coinfection
Interventions: Maraviroc, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 24
States / cities: Bakersfield, California • Los Angeles, California • Oakland, California + 16 more

Conditions: Hepatitis C, HIV, Type2 Diabetes
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiac Transplant Disorder, Hepatitis C
Interventions: Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin; Drug
Lead sponsor: Raymond T. Chung, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic, Liver Diseases
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 21 Years and older
Enrollment: 1,601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Davis, California • New Haven, Connecticut • Gainesville, Florida + 8 more

Conditions: Hepatitis C Virus Infection
Interventions: Simeprevir, Sofosbuvir; Drug
Lead sponsor: Janssen Infectious Diseases BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 32
States / cities: Dothan, Alabama • Bakersfield, California • Chula Vista, California + 29 more

Search by objective public record fields.

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

Direct Acting Antiviral-Post Authorization Safety Study

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Ph IIA Study (SOC +/- NS5B)

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Eliminating Hepatitis C Virus

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

The Patient-Reported Outcomes Project of HCV-TARGET

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis